•  
  •  
 

Abstract

BACKGROUND: The risk of acquiring both hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in patients with cancer has been documented. Risk of parenteral transmission of viral hepatitis has been well recognized, especially due to blood product transfusions. PATIENTS AND METHODS: The duration of the data collection and analysis of the study was from August 2018 till October 2019. A retrospective study included 92 children with Acute Lymphoblastic Leukemia diagnosed consecutively in a 2-year period; 2015-2016 at Oncology Unit in Children Welfare Teaching Hospital. Demographic information, treatment details, vaccination history and baseline hepatitis screen were documented. Follow up data during ALL therapy regarding the mass of blood products received by the patients, RESULTS: At the time of diagnosis, all patients were serologically negative from HBV and HCV. During the follow up period, there were 19 (20.6%) patients infected with hepatitis by serological method; 18 with hepatitis C and one with hepatitis B. there was no significant correlation between seroconversion with hepatitis and liver dysfunction, blood product transfusions more than 10 times, chemotherapy delay due to liver dysfunction and risk group. The mean duration from date of diagnosis till date of last follow up was 43.7 months (range 28.6-56.2 months), while the duration from date of diagnosis till seroconversion with hepatitis was 44.2 months (range 6.9-56.4 months). CONCLUSION: Low incidence of HBV and high incidence of HCV noticed in this group of patients, there is no direct significant correlation to blood product transfusions.    

DOI

10.52573/ipmj.2024.182889

Download

Share

COinS